ACUMEN PHARMACEUTICALS INC. - COMMON STOCK

Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference

06 Nov 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

06 Nov 2024 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024

05 Nov 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference

31 Oct 2024 05:05:25 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

23 Oct 2024 05:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference

30 Sep 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

26 Sep 2024 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

25 Sep 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference

03 Sep 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

13 Aug 2024 04:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024

06 Aug 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

29 Jul 2024 04:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

28 Jul 2024 04:30:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024

11 Jul 2024 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

14 May 2024 04:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

13 May 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference

08 May 2024 14:47:25 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

08 May 2024 05:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

07 May 2024 13:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting

16 Apr 2024 05:00:00 By Nasdaq GlobeNewswire